Q4 2024 · 13F-HR
Patient Square Capital LPholdings as filed
Filed 2025-02-14 · accession 0000950123-25-002377
$267.4M
Reported value
20
Positions
2024-12-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| G76279101 | ROIV | ROIVANT SCIENCES LTD | $147.6M | 55.2% | 12,480,000 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $21.9M | 8.18% | 1,860,371 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $21.2M | 7.93% | 307,167 | Common | SOLE |
| 230031106 | CGEM | CULLINAN THERAPEUTICS INC | $10.7M | 4.00% | 878,897 | Common | SOLE |
| 30233G209 | EYPT | EYEPOINT PHARMACEUTICALS | $10.5M | 3.93% | 1,410,331 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS, INC. | $8.4M | 3.14% | 446,296 | Common | SOLE |
| 46116X101 | ITCIEUR | INTRA-CELLULAR THERAPIES INC. | $6.0M | 2.25% | 71,990 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $5.0M | 1.89% | 224,038 | Common | SOLE |
| 374163103 | GERN | GERON CORPORATION | $4.7M | 1.75% | 1,321,268 | Common | SOLE |
| 67576A100 | OCUL | OCULAR THERAPEUTIX, INC. | $4.0M | 1.50% | 470,919 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS, INC. | $4.0M | 1.50% | 121,732 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $4.0M | 1.49% | 207,603 | Common | SOLE |
| 254604101 | IRON | DISC MEDICINE, INC. | $3.6M | 1.34% | 56,400 | Common | SOLE |
| 85205L107 | SWTXUSD | SPRINGWORKS THERAPEUTICS, INC. | $3.4M | 1.26% | 93,137 | Common | SOLE |
| 019770106 | ALLO | ALLOGENE THERAPEUTICS, INC. | $3.2M | 1.19% | 1,489,909 | Common | SOLE |
| 604749101 | MIRM | MIRUM PHARMACEUTICALS, INC. | $2.7M | 1.00% | 64,900 | Common | SOLE |
| 45826J105 | NTLA | INTELLIA THERAPEUTICS, INC. | $2.5M | 0.94% | 215,981 | Common | SOLE |
| 04335A105 | ARVN | ARVINAS, INC. | $1.7M | 0.62% | 86,627 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HOLDING CORPORATION | $1.4M | 0.52% | 32,000 | Common | SOLE |
| 04635X102 | CATBUSD | ASTRIA THERAPEUTICS INC | $939,210 | 0.35% | 105,057 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.